



Crescendo Biologics shortlisted for 'Most Impactful UK Deal' at 2022 OBN Awards

Cambridge, UK, 13 September 2022 – Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that it has been shortlisted into the final round in the 'Most Impactful UK Deal' category of the 2022 OBN Awards.

In January 2022, Crescendo and BioNTech [announced](#) a global, multi-target discovery and development collaboration to leverage the unique technologies and expertise of each company to create novel precision immunotherapies for cancer and other diseases. Crescendo is using its unique, proprietary, transgenic platform to generate fully human, heavy-chain antibody domains (Humabody® V_H) against targets nominated by BioNTech.

Humabody V_H represent a novel class of therapeutics that retain the high-affinity binding and specificity of conventional therapeutic antibodies while providing additional advantages such as enhanced tissue and tumour penetration and exceptional stability. This high-value deal, with an initial term of three years, yielded \$40 million upfront to Crescendo, including an equity investment by BioNTech, with more than \$750 million in development, regulatory and commercial milestones as well as tiered royalties on future sales.

Details of the **2022 OBN Awards** ceremony are as follows:

Date: Thursday 17 November 2022, from 18.30

Venue: Royal Lancaster Hotel, Lancaster Terrace, London W2 2TY

For more information: <https://obn.glueup.com/event/obn-awards-2022-52570>

The OBN Awards, now in their 14th year, are a highly regarded and sought-after awards programme for the life sciences industry, designed to celebrate innovation and outstanding achievement across all corners of the life sciences industry. The different award categories shine a light on companies at all stages of development, recognising inspirational leadership, exciting innovation, novel and exciting approaches to unmet clinical needs, outstanding company progression and the delivery of real-life, tangible results.

-Ends-



For more information, please contact:

Crescendo Biologics

Michael Booth, CFO
+ 44 (0)1223 497140
investors@crescendobiologics.com
media@crescendobiologics.com

Instinctif Partners

Melanie Toyne-Sewell
Manisha Kuttetira
+ 44 (0)20 7457 2020
crescendo@instinctif.com

About Crescendo Biologics

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours ([NCT04839991](https://clinicaltrials.gov/ct2/show/study/NCT04839991)). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo's T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1xLAG-3 multi-specific Humabody.

The Company's ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human V_H domain building blocks (Humabody V_H). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications.

Beyond Crescendo's proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital.

For more information, please visit www.crescendobiologics.com and follow [@HUMABODY](https://twitter.com/HUMABODY).